391.22MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Y-mAbs Therapeutics Inc
Currency: USD Updated: 2025-09-16 Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals.
Y-mAbs Therapeutics Inc's Score
Score Analysis
Current score
Previous score
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Y-mAbs Therapeutics Inc Highlights
StrengthsRisks
Financial Health
Currency: USD Updated: 2025-09-16 Its latest quarterly revenue reached 19.52M, representing a year-over-year decrease of 14.36%, while its net profit experienced a year-over-year decrease of 64.98%.
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Key Metrics
Total revenue
Operating profit
Total assets
SG&A
No Data
Key Metrics
Cash flow from operating activities
Income after tax
No Data
Key Metrics
Cash flow from operating activities
Total revenue
No Data
Key Metrics
No Data
Y-mAbs Therapeutics Inc's Company Valuation
Currency: USD Updated: 2025-09-16The company’s current valuation score is 6.25, which is higher than the Pharmaceuticals industry's average of 2.09. Its current P/E ratio is 0.00, which is -Inf% below the recent high of -6.28 and +Inf% above the recent low of -19.21.
Valuation Dimensions
Industry Ranking 57/176
No Data
Earnings Forecast
Currency: USD Updated: 2025-09-16The company’s current earnings forecast score is 6.00, which is lower than the Pharmaceuticals industry's average of 7.76. The average price target for Y-mAbs Therapeutics Inc is 8.60, with a high of 8.60 and a low of 3.00.
Support & Resistance
No Data
No Data
Financial Forecasting
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-09-16The company’s current price momentum score is 6.62, which is lower than the Pharmaceuticals industry's average of 6.69.
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Institutional Confidence
Currency: USD Updated: 2025-09-16The latest institutional shareholding proportion is 82.95%, representing a quarter-over-quarter decrease of 2.97%. The largest institutional shareholder is The Vanguard, holding a total of 1.94M shares, representing 4.28% of shares outstanding, with 3.47% decrease in holdings.
Institutional Shareholding
No Data
Shareholder Activity
Paradigm BioCapital Advisors LP
Beryl Capital Management, LLC
Acorn Capital Advisors, LLC
BlackRock Institutional Trust Company, N.A.
Sofinnova Investments, Inc
Risk Assessment
Currency: USD Updated: 2025-09-16The company’s current risk assessment score is 2.91, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.49. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Beta vs S&P 500 index
0.49
240-Day Maximum Drawdown
+100.00%
Volatility
Downside Risk-Adjusted Return
Maximum Daily Upside Volatility
Maximum Daily Downside Volatility
Y-mAbs Therapeutics Inc
YMAB
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
ANI Pharmaceuticals Inc
ANIP
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
COLL
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ligand Pharmaceuticals Inc
LGND
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
